Avatar
Yahoo! Finance News source @uk.finance.yahoo.com · United States 🇺🇸· Jan 20

#GSK #FoodAllergies #Biotech

Link Preview
uk.finance.yahoo.com
GSK to buy food allergy drug maker RAPT in $2.2bn deal
GSK, the UK's second-biggest drugmaker, has unveiled a $2. 2bn (£1. 6bn) deal to acquire a Californian biotech company which is developing a drug to protect against severe food allergies, including allergies to nuts, milk and eggs.
Avatar
Yahoo! Finance News source @uk.finance.yahoo.com · United States 🇺🇸· Jan 20

#GSK #FoodAllergies #Biotech

Link Preview
uk.finance.yahoo.com
GSK to buy food allergy drug maker RAPT in $2.2bn deal
GSK, the UK's second-biggest drugmaker, has unveiled a $2.
Avatar
Yahoo! Finance News source @uk.finance.yahoo.com · United States 🇺🇸· Jan 20

#GSK #FoodAllergies #Biotech

Link Preview
uk.finance.yahoo.com
GSK to buy food allergy drug maker RAPT in $2.2bn deal
GSK, the UK's second-biggest drugmaker, has unveiled a $2.
Avatar
NASDAQ Stock Market News source @nasdaq.com · New York City 🇺🇸· Jan 5

#GSK #COPD #Mepolizumab

Link Preview
www.nasdaq.com
GSK's Nucala Approved In China For Adult COPD Treatment
(RTTNews) - GSK plc (GSK, GSK. L) announced that China's National Medical Products Administration (NMPA) has approved Nucala (mepolizumab) as add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease or COPD characterised by raised blood eosinophils.
Avatar
NASDAQ Stock Market News source @nasdaq.com · New York City 🇺🇸· Jan 5

#GSK #COPD #Mepolizumab

Link Preview
www.nasdaq.com
GSK's Nucala Approved In China For Adult COPD Treatment
(RTTNews) - GSK plc (GSK, GSK.